Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA's Rx Promotion Citation Drought Continued In 2015

This article was originally published in The Pink Sheet Daily

Executive Summary

First Amendment litigation and guidance document work may be factors behind decline.

Advertisement

Related Content

FDA’s Rx Promo Citations Rise Slightly In 2016; Investigational Drug Promos Scrutinized
FDA’s Promotional Enforcement Still Playing It Safe
FDA's Drug Promotion Advisory Reviews Taking Longer
DTC Rx Drug Ad Study No. 30: Do Market Claims Impact Perception?
FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
DTC Print Ads: Package Insert Info Is Out, Drug Facts Box Is In

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS079067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel